Evidence map›Paper›PMID 24920818›Full record

ArticleJournal of virology2014

Comprehensive analysis of contributions from protein conformational stability and major histocompatibility complex class II-peptide binding affinity to CD4+ epitope immunogenicity in HIV-1 envelope glycoprotein.

Tingfeng Li, N Kalaya Steede, Hong-Nam P Nguyen, Lucy C Freytag, James B McLachlan, Ramgopal R Mettu, James E Robinson, Samuel J Landry

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tingfeng LiDepartment of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
N Kalaya SteedeDepartment of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Hong-Nam P NguyenDepartment of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Lucy C FreytagDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
James B McLachlanDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Ramgopal R MettuDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, Louisiana, USA.
James E RobinsonDepartment of Computer Science, Tulane University, New Orleans, Louisiana, USA.
Samuel J LandryDepartment of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, Louisiana, USA landry@tulane.edu.
Tulane University · US

Funding

HIV ENV epitope engineeringR01AI080367 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI LANDRY, SAMUEL JOHN · 2009 to 2011
$1.1M
NIAID NIH HHS R01 AI080367NIAID NIH HHS R01-AI080367
6 · The paper itself

Abstract

unlabelledHelper T-cell epitope dominance in human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 is not adequately explained by peptide binding to major histocompatibility complex (MHC) proteins. Antigen processing potentially influences epitope dominance, but few, if any, studies have attempted to reconcile the influences of antigen processing and MHC protein binding for all helper T-cell epitopes of an antigen. Epitopes of gp120 identified in both humans and mice occur on the C-terminal flanks of flexible segments that are likely to be proteolytic cleavage sites. In this study, the influence of gp120 conformation on the dominance pattern in gp120 from HIV strain 89.6 was examined in CBA mice, whose MHC class II protein has one of the most well defined peptide-binding preferences. Only one of six dominant epitopes contained the most conserved element of the I-Ak binding motif, an aspartic acid. Destabilization of the gp120 conformation by deletion of single disulfide bonds preferentially enhanced responses to the cryptic I-Ak motif-containing sequences, as reported by T-cell proliferation or cytokine secretion. Conversely, inclusion of CpG in the adjuvant with gp120 enhanced responses to the dominant CD4+ T-cell epitopes. The gp120 destabilization affected secretion of some cytokines more than others, suggesting that antigen conformation could modulate T-cell functions through mechanisms of antigen processing. IMPORTANCE: CD4+ helper T cells play an essential role in protection against HIV and other pathogens. Thus, the sites of helper T-cell recognition, the dominant epitopes, are targets for vaccine design; and the corresponding T cells may provide markers for monitoring infection and immunity. However, T-cell epitopes are difficult to identify and predict. It is also unclear whether CD4+ T cells specific for one epitope are more protective than T cells specific for other epitopes. This work shows that the three-dimensional (3D) structure of an HIV protein partially determines which epitopes are dominant, most likely by controlling the breakdown of HIV into peptides. Moreover, some types of signals from CD4+ T cells are affected by the HIV protein 3D structure; and thus the protectiveness of a particular peptide vaccine could be related to its location in the 3D structure.

Indexed as

AnimalsEpitopesFemaleHistocompatibility Antigens Class IIHIV Envelope Protein gp120Mice, Inbred CBAProtein BindingProtein ConformationProtein StabilityEpitopesgp120 protein, Human immunodeficiency virus 1Histocompatibility Antigens Class IIHIV Envelope Protein gp120

Identifiers

PMID24920818
PMCPMC4136326
OpenAlexW2170290365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.